CERT closed at $7.80 on Tuesday, down -4.65% from $8.18, after an extreme intraday swing from a low of $6.33 to a high of $7.83 on heavy volume of 10.8M shares. The move followed a steep premarket gap down of nearly -19% after Q2 2026 earnings were released before the open, with the stock recovering substantially during the regular session.

REZI closed at $26.17 on Tuesday, plunging -27.77% ($10.06) from its previous close of $36.23, with the entire move occurring during regular trading hours. The decline is a mechanical price adjustment following the completion of the ADI Global Distribution spin-off, with ADI beginning independent trading on the NYSE under ticker ADIG on August 4.

Element Solutions shares have declined approximately 8% over the past 30 days as the initial merger premium from the Solstice Advanced Materials acquisition announcement continues to erode. The $14.5 billion cash-and-stock buyout, announced July 6, valued ESI at roughly $50.10 per share — a level the stock has since drifted significantly below amid shareholder dissatisfaction on both sides.

AHCO plunged -38.13% during Tuesday's regular session, closing at $6.70 after reporting Q2 2026 results that severely missed expectations across all key metrics. The primary catalyst was a disastrous Q2 earnings report: adjusted EPS of -$0.99 versus consensus of +$0.15, and revenue of $740.3M missing the $848.9M estimate.

Price target in focus: $60 per share — a level that would represent a new all-time high and roughly 33% upside from the latest closing price near $45. Strongest bullish factors: Robust revenue growth, a low P/E ratio of approximately 11, an asset-light B2B marketplace model, accelerating international expansion, and active share buybacks.

GigaCloud Technology (GCT) shares surged approximately 39% between early July and early August 2026, climbing from $33.21 to $46.23. Over the broader quarter, the stock followed a volatile path — falling sharply after its Q1 2026 earnings beat in early May, bottoming near $31.50 in June, then staging a powerful recovery.

VERX plunged -13.73% during regular trading on Tuesday, extending a pre-market decline of roughly -2% after the company's Q2 2026 results sparked a sharp selloff. The Q2 earnings and revenue beat consensus ($0.20 EPS vs. $0.19; $203.97M vs. $202.30M), but Q3 revenue guidance of $208M–$211M missed the $211.70M Street estimate, rattling investors.

UL Solutions shares plunged -14.71% to $77.66 during regular trading after reporting Q2 2026 results that beat estimates but sparked deepening investor concerns throughout the session. Q2 earnings beat handily — adjusted EPS of $0.59 vs. $0.51 consensus — and revenue rose +5.2% YoY to $816 million with record adjusted EBITDA margin of 26.8%, yet the stock sold off sharply.

AIN plunged approximately -14.6% during regular trading hours, falling from a prior close of $75.12 to around $64.17 after reporting Q2 2026 earnings. The company posted Q2 adjusted EPS of $0.82, beating the $0.74 consensus, but revenue of $329.5 million missed estimates of $342.5 million, triggering the selloff.

Centuri Holdings shares plunged -17.44% during regular trading on Tuesday following the release of Q2 2026 results, with the stock dropping from a prior close of $27.86 to approximately $23.00. The decline came despite record quarterly revenue of $962 million (+33% YoY), as investors focused on deteriorating profitability metrics including a 2% rise in gross profit that sharply lagged revenue growth.

REZI shares dropped -24.95% to $27.19 during regular market trading on August 4, 2026, following the completed spin-off of its ADI Global Distribution unit. The decline is a mechanical corporate-action adjustment: REZI distributed one ADI share for every two REZI shares held, and ADI began trading independently today on the NYSE under ticker "ADIG."

AHCO shares plunged approximately -41.50% during regular trading after the company reported Q2 2026 results that missed consensus estimates across all key metrics. The company posted a GAAP loss of -$0.99 per share, dramatically below the analyst consensus of +$0.15 profit, driven largely by a $144.2 million non-cash goodwill impairment charge.

CBT plunged -11.23% during Tuesday's regular session, extending a -4.58% premarket decline after reporting Q3 fiscal 2026 results that beat on adjusted EPS ($1.67 vs. $1.65 consensus) and revenue ($982M vs. $943M expected) but revealed deep cracks beneath the surface. GAAP net income collapsed to $6M ($0.12/share) from $101M ($1.86/share) a year ago, weighed down by $78M in restructuring charges and one-time costs that spooked investors despite the headline adjusted earnings beat.

BRKR shares plunged -18.02% to $52.72 during regular trading after reporting Q2 2026 results before the open, erasing recent gains from a prior close of $64.31. The primary catalyst was a top-and-bottom-line miss: revenue of $838.5M fell -1.9% short of the $854.8M consensus, and full-year revenue guidance was cut to $3.56B at the midpoint from $3.59B.

APTV plunged -14.50% to approximately $48.93 during Tuesday's regular session, with the selloff igniting in premarket trading where shares had already dropped -11.9% following the company's Q2 2026 earnings release. Q2 adjusted EPS of $1.63 handily beat the $1.42 consensus and revenue of $3.3 billion met estimates, but the earnings beat was completely overshadowed by a sharp cut to full-year guidance.

CIFR plunged -12.5% during Tuesday's regular session after trading down roughly -9% in the premarket, driven by a severe Q2 earnings miss. The company reported Q2 revenue of $24.8 million ($32.5M expected), EPS of -$0.65 (-$0.23 expected), and an adjusted EBITDA loss of $30 million, far below the estimated +$218.7 million.

STRL is down approximately -14% during Tuesday's regular session, extending a -4.7% after-hours decline following its Q2 2026 earnings release on August 3. Q2 results were objectively strong — revenue surged +90% YoY to $1.17B and adjusted EPS more than doubled to $5.80 — but the market fixated on margin pressures.

FIS shares plunged -10.07% to $40.27 during Tuesday's regular session after falling more than -10% in premarket trading, following the company's Q2 2026 earnings report and sharply reduced forward guidance. The company slashed its full-year 2026 adjusted EPS forecast to $6.15–$6.24 from $6.22–$6.32 and cut its revenue outlook to $13.63B–$13.70B from $13.77B–$13.85B, with both Q3 EPS and revenue guidance also coming in below consensus.

Target in focus: Piper Sandler's $77 price target represents roughly 40% upside from Moderna's recent close of $55.14, making it the most bullish Wall Street objective currently on the table. Strongest bullish factors: An imminent FDA decision on the company's mRNA flu vaccine (mFLUSIVA), advancing oncology pipeline assets including the closely watched intismeran autogene melanoma program, and a fortified balance sheet with approximately $5.96 billion in pro forma cash.

FTAI Aviation shares have pulled back roughly 9% over the past 30 days, retreating from approximately $248 to the $225 area, following a second-quarter earnings report that missed consensus EPS estimates despite record quarterly revenue. The company reported Q2 2026 revenue of $953 million, up 40.9% year-over-year, while adjusted EPS of $1.13 came in below the $1.32 analyst consensus, triggering post-earnings selling pressure.